



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

NANO:002US

Serial No.

09/748,133

Applicant

Russell Mumper

Filing Date:

December 27, 2000

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|----------|------------------|-------|-----------|---------------------|
| | A1 | 4,517,173 | 05/14/85 | Kizawa et al. | 424 | 16 | 09/25/81 |
| | A2 | 4,715,369 | 12/29/87 | Suzuki et al. | 128 | 156 | 02/09/87 |
| | A3 | 4,959,218 | 09/25/90 | Eckenhoff et al. | 424 | 473 | 12/28/88 |
| | A4 | 5,700,478 | 12/23/97 | Biegajski et al. | 424 | 434 | 09/19/94 |
| | A5 | 3,922,260 | 11/25/75 | Peniston et al. | 260 | 211 | 08/24/73 |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|-------------|-----------|-----------------|----------|------------|-------|-----------|--------------------|
| | B1 | EP 0 435 199 | 07/03/91 | Europe EPD | | | English |
| | B2 | WO 00 10536 | 03/02/00 | WIPO | | | English |
| | B3 | WO 00 59423 | 10/12/00 | WIPO | | | English |
| | B4 | WO 98 17251 | 04/30/98 | WIPO | | | English |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C1 | Bechgaard et al., "Solubilization of various benzodiazepines for intranasal administration, a pilot study," <i>Pharm Dev Tech</i> , 2:293-296, 1997. |
| | C2 | Binnie et al., "Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers," <i>Compend Contin Educ Dent</i> , 18:1116-1118, 1997. |
| | C3 | Casetta and Negretti, "Salivary immune responses after gingival immunization with tetravaccinal and bivaccinal formulations of inactivated micro-organisms," <i>Dev Biol Stand</i> , 92:317-321, 1998. |
| | C4 | Chang, "Stability of hirudin, a thrombin-specific inhibitor," <i>J Biol Chem</i> , 266:10839-10843, 1991. |
| | C5 | Eric and Caroline, "Influence of storage conditions on the activity of recombinant hirudin," <i>Thromb Res</i> , 61:87-89, 1991. |

25555672.1

EXAMINER:

DATE CONSIDERED:

12/03/2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
NANO:002USSerial No.
09/748,133Applicant
Russell MumperFiling Date:
December 27, 2000Group:
1615U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| CA | C6 | Eriksson <i>et al.</i> , "Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement," <i>J Bone Joint Surg Am</i> , 79:326-333, 1997. |
| | C7 | Esslinger <i>et al.</i> , "Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers," <i>Throm Haemost</i> , 77:911-919, 1997. |
| | C8 | Etchart <i>et al.</i> , "Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus hemagglutinin," <i>J Gen Virol</i> , 78:1577-1580, 1997. |
| | C9 | Fenton <i>et al.</i> , "Thrombin inhibition by hirudin: how hirudin inhibits thrombin," <i>Haemostasis</i> , 21:27-31, 1991. |
| | C10 | Fenton, "Thrombin interactions with hirudin," <i>Sem Thromb Hemost</i> , 15:265-268, 1989. |
| | C11 | Garcia-Closas <i>et al.</i> , "Epidemiologic determinants of vaginal pH," <i>Am J Obstet Gynecol</i> , 180:1060-1066, 1999. |
| | C12 | Heath <i>et al.</i> , "Mechanism of triclosan inhibition of bacterial fatty acid synthesis," <i>J Biol Chem</i> , 274:11110-11114, 1999. |
| | C13 | Hjortkjaer <i>et al.</i> , "Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines," <i>J Pharm Pharmacol</i> , 51:377-383, 1999. |
| | C14 | Jones <i>et al.</i> , "Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes," <i>Biochim Biophys Acta</i> , 1147:251-261, 1993. |
| | C15 | Khandwala <i>et al.</i> , "5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. clinical demonstration of acceleration of healing and resolution of pain," <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i> , 83:222-230, 1997a. |
| | C16 | Khandwala <i>et al.</i> , "5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: II. Pharmacokinetics and demonstration of clinical safety," <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i> , 83:231-238, 1997b. |
| CA | C17 | Leopold and Eikeler, "Eudragit E as a coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)," <i>J Drug Targeting</i> , 6:85-94, 1998. |

25555672.1

EXAMINER:

DATE CONSIDERED:

12/09/2005

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

U.S. Department of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

NANO:002US

Serial No.

09/748,133

Applicant

Russell Mumper

Filing Date:

December 27, 2000

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| A | C18 | Leung <i>et al.</i> , "Mucoadhesive dosage forms for peptide and protein drug delivery," In: <i>Peptide and Protein Drug Delivery</i> , V.H.L. Lee ed. Marcel Dekker, Inc. New York, pp. 741-767, 1991. |
| | C19 | Liu <i>et al.</i> , "DNA vaccines: A new era in vaccinology," <i>Ann NY Acad Sci</i> , New York, NY, 772. 1995. |
| | C20 | Loftsson <i>et al.</i> , "Effect of cyclodextrins and polymers on triclosan availability and substantivity in toothpastes in vivo," <i>J Pharm Sci</i> , 88:1254-1258, 1999. |
| | C21 | Mandel, "Antimicrobial mouthrinses: overview and update," <i>J Am Dent Assoc</i> , 125:2S-10S, 1994. |
| | C22 | March and Nakamura, "Evaluation of the duration of effect of a bioadhesive vaginal moisturizing gel on vaginal pH," 7 th International Congress on the Menopause, Replens Symposium, Stockholm, Sweden, June 20-22, 1993. |
| | C23 | Markwardt, "Development of hirudin as an antithrombotic agent," <i>Sem THromb Hemost</i> , 15:269-282, 1989. |
| | C24 | Markwardt, "Past, present and future of hirudin," <i>Haemostasis</i> , 21:11-26, 1991b. |
| | C25 | Markwart, "Hirudin and derivatives as anticoagulant agents," <i>Thromb Haemost</i> , 66:141-152, 1991a. |
| | C26 | Martin <i>et al.</i> , <i>Martin's Physical Pharmacy: Physical chemical principles in the pharmaceutical sciences</i> , Lea & Febiger, Third Ed., Philadelphia, 1983. |
| | C27 | McGhee and Kiyono, "Mucosal immunity to vaccines: Current concepts for vaccine development and immune response analysis," In: J.E. Ciarli (ed.) <i>Genetically engineered vaccines</i> , Plenum Press, New York, NY, pp. 3-12, 1992a. |
| | C28 | Park and Robinson, "Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion," <i>J Cont Rel</i> , 2:47-57, 1985. |
| | C29 | Rathbone <i>et al.</i> , In: <i>Oral J Mucosal Drug Delivery</i> , M.J. Rathbone Ed., Marcel Dekker Inc., New York, 1996. |
| | C30 | <i>Remington's Pharmaceutical Sciences</i> , 18 th Ed., A.R. Gennard, ed. Mack Publishing Company, Easton, PA, 1990. |
| | C31 | Riehl-Bellon <i>et al.</i> , "Purification and biochemical characterization of recombinant hirudin produced by <i>Saccharomyces cerevisiae</i> ," <i>Biochemistry</i> , 28:2941-2949, 1989. |
| OA | C32 | Robinson and Torres, "C.A.T. DNA Vaccines," <i>Sem Immun</i> , 9:271-283, 1997. |

25555672.1

EXAMINER:

DATE CONSIDERED:

12/09/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
NANO:002USSerial No.
09/748,133

List of Patents and Publications for Applicant's

Applicant
Russell Mumper

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 27, 2000Group:
1615U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| CA | C33 | Saijo <i>et al.</i> , "Inhibition by amoxanox (AA-673) of the immunologically, leukotriene D4- or platelet-activating factor-stimulated bronchoconstriction in guinea pigs and rats," <i>Int Arch Allergy Appl Immunol</i> , 77:315-321, 1985. |
| | C34 | Saijo <i>et al.</i> , "The antiallergic agent amoxanox suppresses SRS-A generation by inhibiting lipoxygenase," <i>Int Arch Allergy Appl Immunol</i> , 79:231-237, 1986. |
| | C35 | Schwagmeier <i>et al.</i> , "Midazolam pharmacokinetics following intravenous and buccal administration," <i>Br J Clin Pharmacol</i> , 46:203-206, 1998. |
| | C36 | Spannagl <i>et al.</i> , "A fast photometric assay for the determination of hirudin," <i>Haemostasis</i> , 21:36-40, 1991. |
| | C37 | Stevens-Simon <i>et al.</i> , "Racial variation in vaginal pH among healthy sexually active adolescents," <i>Sex Transm Dis</i> , 21:168-172, 1994. |
| | C38 | Tang <i>et al.</i> , "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356:152-154, 1992. |
| | C39 | Taubes, "Salvation in a snippet of DNA," <i>Science</i> , 278:1711-1714, 1997. |
| | C40 | Ulmer <i>et al.</i> , "Toward the development of DNA vaccines," <i>Curr Opin Immun</i> , 8:531-536, 1996a. |
| | C41 | Urisu <i>et al.</i> , "Inhibitory action amlexanox on interleukin-3-induced enhancement of histamine releasability of human leukocytes," <i>Arerugi</i> , 39(10):1448-1454, 1990. (ABSTRACT) |
| | C42 | Yankauckas <i>et al.</i> , "Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene," <i>DNA Cell Biol</i> , 12:771-776, 1993. |
| | C43 | Zuckerbraun <i>et al.</i> , "Triclosan: cytotoxicity, mode of action, and induction of apoptosis in human gingival cells in vitro," <i>Eur J Oral Sci</i> , 106:628-636, 1998. |
| CA | C44 | Co-Pending US Application No. 10/072,320 filed on February 7, 2002, (NANO:002USD1). |

25555672.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)